What is Lavior?
Lavior operates at the intersection of advanced biotechnology and natural medicine, specializing in the development of treatments for diabetic wounds and complex skin conditions. By leveraging 15 years of rigorous research into the Inula Viscosa AGS RIED species, the company has established a unique market position. Their product portfolio is engineered to address the underlying causes of chronic skin disorders, with a primary clinical objective of preventing amputations and enhancing patient outcomes. Through a recent strategic rebranding, Lavior has solidified its identity as a science-led botanical healing entity, effectively bridging the gap between traditional herbal efficacy and modern clinical standards.
How much funding has Lavior raised?
Lavior has raised a total of $15K across 3 funding rounds:
Multiple Rounds
$15K
Debt (2024): $5K, investors not publicly disclosed
Debt (2024): $5K, investors not publicly disclosed
Debt (2024): $5K supported by First Internet Bancorp
Key Investors in Lavior
First Internet Bancorp
A financial services holding company that provides a range of banking products and services, often supporting growth-stage enterprises through strategic debt financing.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lavior?
With the recent influx of capital, Lavior is well-positioned to accelerate its commercialization strategy and deepen its penetration into global healthcare markets. The company's growth trajectory, characterized by a transition from research-heavy development to a scaling phase, suggests a focus on expanding distribution channels and potentially initiating further clinical validation studies. As the firm navigates the Series A/B growth stage, the emphasis will likely remain on scaling its manufacturing capabilities and broadening its reach to healthcare providers who prioritize non-invasive, botanical-based interventions for diabetic patients. This strategic deployment of resources is expected to fortify Lavior's competitive moat in the specialized wound care sector.
See full Lavior company page
